U.S. House Advances Farm Bill Without Hemp Cannabinoid Amendments
The U.S. House of Representatives has passed the Farm, Food, and National Security Act of 2026, a federal Farm Bill that notably omits provisions to alter or delay impending federal changes to hemp-derived cannabinoid regulations. The bill passed with a vote of 224-200 on Tuesday, as reported by Ganjapreneur. This legislative step maintains the current trajectory for the hemp industry, particularly concerning intoxicating hemp-derived products.
The initial federal legalization of industrial hemp occurred through the 2018 Farm Bill, enacted during President Trump’s administration. This legislation defined hemp as cannabis containing less than 0.3% THC, and extended this definition to include all derivatives of the hemp plant. This framework inadvertently facilitated the emergence of a national market for hemp-derived cannabinoids, where operators developed methods to convert hemp-derived CBD into compounds such as delta-8 THC and other intoxicating cannabinoids. This segment of the industry subsequently expanded into a multi-billion-dollar market.
Regulatory Landscape and Industry Impact on Hemp-Derived Cannabinoids
The operational environment for the hemp-derived cannabinoid industry shifted significantly last year. President Trump signed a spending bill that included language intended to restrict the nationwide sale of intoxicating hemp products, introducing considerable uncertainty for businesses operating in this space. The current Farm, Food, and National Security Act of 2026, while passed by the House, does not include language that would provide a reprieve or new regulatory framework for these specific products.
According to the Ganjapreneur report, the hemp provisions within the Farm Bill primarily aim to:
- Clarify existing regulations for industrial hemp.
- Reduce administrative and operational burdens for industrial hemp farmers across the U.S.
However, the absence of specific amendments regarding intoxicating hemp-derived cannabinoids means that, without further congressional action, the existing industry for these products faces an effective cessation date of November 12, 2026. This deadline stems from the previously enacted spending bill and its implications for the definition and legality of these substances.
Path Forward in the Senate
Following its passage in the House, the Farm Bill now proceeds to the Senate for consideration. Industry advocates and stakeholders are expected to lobby lawmakers in the Senate to propose and adopt amendments that could offer protections or a revised regulatory pathway for the hemp-derived cannabinoid sector. The outcome of the Senate’s deliberations will be critical in determining the future of this segment of the industrial hemp market, as previously covered by Hemp Gazette regarding earlier frameworks for the U.S. Farm Bill.
The legislative process in the Senate will be closely watched by operators, investors, and legal professionals within the industrial hemp sector, particularly those involved in the production and distribution of hemp-derived cannabinoids. The absence of specific protective language in the House-passed bill underscores the continued regulatory challenges and the need for clarity regarding the legality and commercial viability of these products beyond the stated November 2026 deadline.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
